Incyte Corp INCY:NASDAQ

Last Price$65.79NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/22/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$65.31 (19)
Ask (Size)$65.83 (12)
Day Low / HighN/A - N/A
Volume1.8 M
 

View Biotechnology IndustryPeer Comparison as of 10/22/2021

 

Incyte Corp ( NASDAQ )

Price: $65.79
Change: -0.08 (0.12%)
Volume: 1.8 M
4:00PM ET 10/22/2021
 
 

Repligen Corp ( NASDAQ )

Price: $274.95
Change: +4.19 (1.55%)
Volume: 210.5 K
4:00PM ET 10/22/2021
 
 

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $73.74
Change: -1.34 (1.78%)
Volume: 1.0 M
4:00PM ET 10/22/2021
 
 

Exact Sciences Corp ( NASDAQ )

Price: $93.98
Change: -2.22 (2.31%)
Volume: 812.9 K
4:00PM ET 10/22/2021
 
 

Natera Inc ( NASDAQ )

Price: $114.93
Change: +2.61 (2.32%)
Volume: 561.6 K
4:00PM ET 10/22/2021
 

Read more news Recent News

Incyte Signs Distribution Deal for Cancer Therapies With Specialised Therapeutics for Australia, New Zealand and Singapore
4:09AM ET 10/22/2021 MT Newswires

Incyte (INCY) said Thursday it has partnered with Specialised Therapeutics Asia for the distribution of oncology therapies tafasitamab and pemigatinib in...

--RBC Lowers Price Target on Incyte to $85 From $86, Maintains Sector Perform Rating
7:59AM ET 10/06/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Eli Lilly, Incyte Say Olumiant Improved Hair Regrowth in Studies to Treat Alopecia Areata
7:49AM ET 9/30/2021 MT Newswires

Eli Lilly (LLY) and Incyte (INCY) on Thursday reported results from two phase 3 trials showing that Olumiant was superior to placebo in achieving...

Sector Update: Health Care Stocks Trade Lower Pre-Bell Monday
9:19AM ET 9/27/2021 MT Newswires

Health care stocks were trading lower pre-bell Monday. The Health Care SPDR (XLV) was down 0.20% and the iShares NASDAQ Biotechnology Index (IBB) was...

Company Profile

Business DescriptionIncyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE. View company web site for more details
Address1801 Augustine Cut-Off
Wilmington, Delaware 19803
Phone+1.302.498.6700
Number of Employees1,367
Recent SEC Filing09/03/20214
Chairman, President & Chief Executive OfficerHerve Hoppenot
Chief Financial Officer & Executive Vice PresidentChristiana Stamoulis
Chief Medical Officer & Executive Vice PresidentSteven H. Stein
Chief Scientific Officer & Executive VPDashyant Dhanak

Company Highlights

Price Open$65.83
Previous Close$65.87
52 Week Range$64.08 - 101.47
Market Capitalization$14.5 B
Shares Outstanding220.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/02/2021

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings43.28
Earnings per Share$1.75
Beta vs. S&P 500N/A
Revenue$1.9 B
Net Profit Margin12.41%
Return on Equity12.66%

Analyst Ratings as of 10/05/2021

Buy
12
Overweight
0
Hold
8
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset